

Stein Bergan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3927426/publications.pdf>

Version: 2024-02-01

58
papers

1,632
citations

361045

20
h-index

315357

38
g-index

61
all docs

61
docs citations

61
times ranked

1775
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	1.0	374
2	Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients. American Journal of Transplantation, 2001, 1, 382-386.	2.6	124
3	Importance of hematocrit for a tacrolimus target concentration strategy. European Journal of Clinical Pharmacology, 2014, 70, 65-77.	0.8	92
4	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200.	1.0	89
5	Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipientsâ€”A Prospective, Randomized Study. Transplantation, 2015, 99, 2158-2166.	0.5	77
6	Improved prediction of tacrolimus concentrations early after kidney transplantation using theoryâ€”based pharmacokinetic modelling. British Journal of Clinical Pharmacology, 2014, 78, 509-523.	1.1	67
7	MONITORED HIGH-DOSE AZATHIOPRINE TREATMENT REDUCES ACUTE REJECTION EPISODES AFTER RENAL TRANSPLANTATION. Transplantation, 1998, 66, 334-339.	0.5	56
8	Reduced Elimination of Cyclosporine A in Elderly (>65 Years) Kidney Transplant Recipients. Transplantation, 2008, 86, 1379-1383.	0.5	49
9	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drugâ€”Drug Interactions. Therapeutic Drug Monitoring, 2020, 42, 360-368.	1.0	48
10	Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype*. Clinical Pharmacology and Therapeutics, 2002, 72, 333-342.	2.3	46
11	High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. Transplantation, 2017, 101, e273-e279.	0.5	40
12	Patterns of Azathioprine Metabolites in Neutrophils, Lymphocytes, Reticulocytes, and Erythrocytes. Therapeutic Drug Monitoring, 1997, 19, 502-509.	1.0	40
13	Automated Determination of Free Mycophenolic Acid and Its Glucuronide in Plasma From Renal Allograft Recipients. Therapeutic Drug Monitoring, 2003, 25, 407-414.	1.0	36
14	Determination of Digoxin and Digitoxin in Whole Blood. Journal of Analytical Toxicology, 2009, 33, 372-378.	1.7	28
15	NFATâ€”regulated cytokine gene expression during tacrolimus therapy early after renal transplantation. British Journal of Clinical Pharmacology, 2017, 83, 2494-2502.	1.1	25
16	Determination of Inosine Monophosphate Dehydrogenase Activity in Human CD4+ Cells Isolated from Whole Blood During Mycophenolic Acid Therapy. Therapeutic Drug Monitoring, 2006, 28, 608-613.	1.0	24
17	Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: Influence on cure rates and risk of second cancer. Pediatric Blood and Cancer, 2014, 61, 797-802.	0.8	24
18	Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: Assessment of matrix effects and assay performance. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 583-591.	0.6	22

#	ARTICLE	IF	CITATIONS
19	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 665-670.	1.0	22
20	MONITORING OF AZATHIOPRINE TREATMENT BY DETERMINATION OF 6-THIOGUANINE NUCLEOTIDE CONCENTRATIONS IN ERYTHROCYTES. <i>Transplantation</i> , 1994, 58, 803-807.	0.5	21
21	Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 407-414.	1.0	20
22	The CYP3A biomarker 4 β -hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1457-1465.	1.1	19
23	Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. <i>Pediatric Blood and Cancer</i> , 2008, 50, 710-713.	0.8	17
24	Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population. <i>Transplantation Direct</i> , 2017, 3, e332.	0.8	17
25	A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 19-28.	1.0	16
26	Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , 2019, 19, 790-800.	2.6	16
27	Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients—A Cross-Validation Study. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 371-375.	1.0	16
28	Optimisation of Azathioprine Immunosuppression After Organ Transplantation by Pharmacological Measurements. <i>BioDrugs</i> , 1997, 8, 446-456.	2.2	15
29	Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 507-516.	1.4	15
30	Drug target molecules to guide immunosuppression. <i>Clinical Biochemistry</i> , 2016, 49, 411-418.	0.8	13
31	Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance. <i>Kidney International Reports</i> , 2020, 5, 189-198.	0.4	13
32	Analysis of Methylated 6-Mercaptopurine Metabolites in Human Blood Cells. <i>Therapeutic Drug Monitoring</i> , 1997, 19, 663-668.	1.0	13
33	A taste of individualized medicine: physicians' reactions to automated genetic interpretations. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, e143-e146.	2.2	11
34	A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 11-18.	1.0	11
35	Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 710-6.	0.6	11
36	Cyclosporine C2 Levels Have Impact on Incidence of Rejection in De Novo Lung but Not Heart Transplant Recipients: The NOCTURNE Study. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 919-926.	0.3	10

#	ARTICLE	IF	CITATIONS
37	Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. <i>Clinical and Translational Science</i> , 2020, 13, 1327-1335.	1.5	9
38	A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2878-2885.	1.1	8
39	Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro. <i>Transplant International</i> , 2015, 28, 1152-1161.	0.8	7
40	Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-9.	1.0	7
41	Low target tacrolimus in de novo standard risk renal transplant recipients: A single centre experience. <i>Nephrology</i> , 2016, 21, 821-827.	0.7	7
42	Statin-associated muscle symptoms in coronary patients: design of a randomized study. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 162-168.	0.4	7
43	Estimated glomerular filtration rate in stable older kidney transplant recipients-are present algorithms valid? A national cross-sectional cohort study. <i>Transplant International</i> , 2018, 31, 629-638.	0.8	6
44	Bodyweight adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1350-1352.	1.1	5
45	Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1100-1112.	1.1	5
46	Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients. <i>Transplant International</i> , 2006, 19, 44-53.	0.8	4
47	Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 203, 114216.	1.4	4
48	Prediction of Fat-Free Mass in Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 439-446.	1.0	3
49	Pharmacology Portal: An Open Database for Clinical Pharmacologic Laboratory Services. <i>Clinical Therapeutics</i> , 2016, 38, 222-226.	1.1	3
50	Therapeutic Drug Monitoring in the Era of Precision Medicine. <i>Therapeutic Drug Monitoring</i> , 2021, Publish Ahead of Print, 719-727.	1.0	3
51	TDM: Report Concentration, C_{ss} , Rather Than Area under the Curve, AUC. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 743.	1.0	2
52	Cardiovascular remodeling in living kidney donors with reduced glomerular filtration rate: rationale and design of the CENS study. <i>Blood Pressure</i> , 2020, 29, 123-134.	0.7	2
53	In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 129, 427-436.	1.2	2
54	Response to: Bodyweight adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance™. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1357-1358.	1.1	1

#	ARTICLE	IF	CITATIONS
55	Monitoring Simvastatin Adherence in Patients with Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma. <i>Therapeutic Drug Monitoring</i> , 2022, Publish Ahead of Print, .	1.0	1
56	Diastolic Time in Patients Treated with Timolol or Placebo after Acute Myocardial Infarction. <i>American Journal of Noninvasive Cardiology</i> , 1993, 7, 220-224.	0.1	0
57	The Authorsâ€™ Reply. <i>Transplantation</i> , 2018, 102, e43-e44.	0.5	0
58	Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipientâ€”No Intervention Actually Needed. <i>Transplantation Direct</i> , 2020, 6, e609.	0.8	0